...
首页> 外文期刊>Proteome science >Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy
【24h】

Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy

机译:1型糖尿病合并糖尿病肾病患者血浆蛋白质组学分析

获取原文

摘要

Background As part of a clinical proteomics program focused on diabetes and its complications we are looking for new and better protein biomarkers for diabetic nephropathy. The search for new and better biomarkers for diabetic nephropathy has, with a few exceptions, previously focused on either hypothesis-driven studies or urinary based investigations. To date only two studies have investigated the proteome of blood in search for new biomarkers, and these studies were conducted in sera from patients with type 2 diabetes. This is the first reported in depth proteomic study where plasma from type 1 diabetic patients was investigated with the goal of finding improved candidate biomarkers to predict diabetic nephropathy. In order to reach lower concentration proteins in plasma a pre-fractionation step, either hexapeptide bead-based libraries or anion exchange chromatography, was performed prior to surface enhanced laser desorption/ionization time-of-flight mass spectrometry analysis. Results Proteomic analysis of plasma from a cross-sectional cohort of 123 type 1 diabetic patients previously diagnosed as normoalbuminuric, microalbuminuric or macroalbuminuric, gave rise to 290 peaks clusters of which 16 were selected as the most promising biomarker candidates based on statistical performance, including independent component analysis. Four of the peaks that were discovered have been identified as transthyretin, apolipoprotein A1, apolipoprotein C1 and cystatin C. Several yet unidentified proteins discovered by this novel approach appear to have more potential as biomarkers for diabetic nephropathy. Conclusion These results demonstrate the capacity of proteomic analysis of plasma, by confirming the presence of known biomarkers as well as revealing new biomarkers for diabetic nephropathy in plasma in type 1 diabetic patients.
机译:背景技术作为针对糖尿病及其并发症的临床蛋白质组学计划的一部分,我们正在寻找糖尿病肾病的新型更好的蛋白质生物标志物。除少数例外,寻找新的和更好的糖尿病肾病生物标记物以前一直集中在假设驱动的研究或基于尿的研究上。迄今为止,只有两项研究调查了血液中的蛋白质组以寻找新的生物标志物,这些研究是在2型糖尿病患者的血清中进行的。这是首次在深度蛋白质组学研究中进行报道,该研究对1型糖尿病患者的血浆进行了研究,目的是发现改善的候选生物标志物以预测糖尿病性肾病。为了在血浆中达到较低浓度的蛋白质,在表面增强的激光解吸/电离飞行时间质谱分析之前,进行了基于六肽珠的文库或阴离子交换色谱的预分离步骤。结果123例先前被诊断为正常白蛋白尿,微量白蛋白尿或大白蛋白尿的1型糖尿病患者的横断面队列血浆的蛋白质组学分析产生了290个峰簇,根据统计性能(包括独立的),其中16个峰簇被选为最有希望的生物标志物候选物成分分析。已发现的四个峰分别是运甲状腺素蛋白,载脂蛋白A1,载脂蛋白C1和胱抑素C。通过这种新方法发现的一些尚未鉴定的蛋白似乎具有更大的潜力,可作为糖尿病性肾病的生物标志物。结论这些结果证实了已知的生物标志物的存在,并揭示了1型糖尿病患者血浆中糖尿病肾病的新生物标志物,从而证明了血浆蛋白质组学分析的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号